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♦	 Background: Endothelial dysfunction, which contributes 
to atherosclerosis and arteriosclerosis, commonly accom-
panies end-stage renal disease (ESRD). However, little is 
known about the role of residual renal function (RRF) in 
endothelial protection in ESRD patients. This study aimed 
to investigate the relationship between endothelial function 
and RRF in patients undergoing peritoneal dialysis (PD).
♦	 Methods: This was a cross-sectional study involving 
72 prevalent PD patients. Demographic and clinical data 
were recorded and residual glomerular filtration rate (GFR), 
Kt/V urea, and serum concentrations of inflammatory mark-
ers were measured. Endothelial function was assessed by 
brachial artery endothelium-dependent vasodilation [flow-
mediated dilation (FMD)] to reactive hyperemia following 
5 minutes of forearm ischemia.
♦	 Results: In patients with FMD% above the median value 
(FMD > 2.41%), residual GFR was significantly higher com-
pared to that in patients with FMD% below the median [1.50 
(0 – 9.64) vs 0.48 (0 – 3.89) mL/min/1.73 m2, P = 0.026]. 
Correlation analyses revealed that residual GFR (ρ = 0.381, 
P = 0.001) and total Kt/V urea (γ = 0.408, P < 0.001) were 
positively correlated with FMD%, whereas PD duration 
(γ = –0.351, P = 0.003), high-sensitivity C-reactive pro-
tein (ρ = –0.345, P = 0.003), pulse pressure (γ = –0.341, 
P = 0.003), and age (γ = –0.403, P < 0.001) were inversely 
correlated with FMD%. In contrast, there was no correlation 
between peritoneal Kt/V urea and FMD%. In multivariate 
linear regression analysis adjusted for these factors, re-
sidual GFR was found to be an independent determinant of 
FMD% (β = 0.317, P = 0.017).
♦	 Conclusion: This study shows that RRF is independently 
associated with endothelial dysfunction in ESRD patients 
on PD, suggesting that RRF may contribute to endothelial 
protection in these patients.
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Cardiovascular disease is the leading cause of morbid- ity and mortality in patients with end-stage renal 
disease (ESRD) (1). The increased risk of cardiovascular 
disease is attributed mainly to the high prevalence of 
traditional risk factors, such as hypertension, diabetes, 
smoking, and dyslipidemia, in this population. Recently, 
accumulating evidence has suggested that nontraditional 
risk factors, including inflammation, oxidative stress, 
and abnormal calcium–phosphorus metabolism, also 
contribute to accelerated atherosclerosis (2,3).
The endothelium modulates vascular tone and struc-
ture by producing and releasing nitric oxide, which also 
exerts a protective role against vascular atherosclerotic 
damage (4). Endothelial dysfunction is an important 
initiating event in the processes of atherosclerosis and 
arteriosclerosis (5) and is affected by both traditional 
and nontraditional risk factors. To date, numerous studies 
have demonstrated that endothelial function is impaired 
in ESRD patients (6,7) and predicts cardiovascular mortal-
ity in these patients, as in the general population (8).
Recently, the importance of residual renal function 
(RRF) has been highlighted in patients with ESRD. 
Decline in RRF is closely linked with fluid overload, ane-
mia, inflammation, malnutrition, and mortality (9,10). 
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lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and intact parathyroid hormone. Residual 
glomerular filtration rate (GFR) was calculated as the 
average clearance of urea and creatinine from a 24-hour 
urine collection (14). Kt/V urea was determined from 
the total loss of urea nitrogen in spent dialysate using 
the Watson equation (15). Estimated average glucose 
exposure was calculated by multiplying the instilled di-
alysate volume by the respective glucose concentration. 
The modified peritoneal equilibration test (13) was per-
formed with 4.25% glucose dialysis solution as described 
previously (16). The dialysate-to-plasma creatinine (D/P 
Cr) and glucose (D/D0 glucose) concentration ratios at 4 
hours of dwell were used to describe the peritoneal small 
solute transport rate. 
This study was approved by the institutional review 
board for human research at our center and informed 
consent was obtained from all patients.
MEASUREMEnT OF InFLAMMATORY BIOMARKERS In SERUM 
AnD PLASMA
High-sensitivity C-reactive protein (hs-CRP) concen-
trations were determined by a latex-enhanced immuno-
nephelometric method using a Bn II analyzer (Dade 
Behring, newark, DE, USA). Interleukin-6 (IL-6) levels 
were measured using an enzyme-linked immuno sorbent 
assay kit (R&D Systems Europe, Abingdon, Oxon, UK) 
and fibrinogen concentrations in citrated plasma by a 
In addition, a decrease in creatinine clearance was 
significantly associated with endothelial dysfunction 
(11) and arterial stiffness (12) in patients with chronic 
kidney disease, suggesting that kidney function plays 
an important role in vascular protection. However, it is 
not clear whether endothelial function is still affected 
by RRF in patients with ESRD. Therefore, in this study, we 
investigated the relationship between endothelial func-
tion and RRF in ESRD patients on continuous ambulatory 
peritoneal dialysis (CAPD).
PATIENTS AND METHODS
STUDY SUBJECTS AnD DATA COLLECTIOn
This was a cross-sectional study of ESRD patients 
undergoing CAPD, who were between 18 and 75 years 
of age and who had been maintained on peritoneal 
dialysis (PD) for more than 3 months. Patients were 
considered eligible for this study if they had no history 
of malignancy or other chronic inflammatory diseases, 
such as systemic lupus erythematosus and rheumatoid 
arthritis, and had no overt infections or acute coronary 
syndrome during the 3 months prior to study entry. Pa-
tients were also excluded if they had a history of kidney 
transplantation or hemodialysis prior to CAPD. In addi-
tion, patients with any signs of volume overload, such as 
jugular vein distension, weight gain > 2 kg per day with 
peripheral pitting edema requiring frequent use of hy-
pertonic PD solutions, or pulmonary congestion on chest 
x ray, were excluded. Of 156 patients screened, 72 were 
included in the final analysis (Figure 1). All patients 
were prescribed Baxter PD solution (Baxter Healthcare 
Corp., Singapore). 
Demographic and clinical data were recorded at study 
entry: age, gender, body mass index calculated as weight/
height2, primary renal disease, previous history of cardio-
vascular disease, and duration of dialysis. Cardiovascular 
disease was defined as a history of coronary, cerebrovas-
cular, or peripheral vascular disease. Coronary disease 
was defined as a history of angioplasty, coronary artery 
bypass grafts, myocardial infarction, or angina. Cere-
brovascular disease was defined as a previous  transient 
ischemic attack, stroke, or carotid endarterectomy, while 
peripheral vascular disease was defined as a history of 
claudication, ischemic limb loss and/or ulceration, or 
peripheral revascular ization procedure. The Charlson 
Comorbidity Index was used to quantify comorbid condi-
tions in the study subjects (13). The following laboratory 
data were measured from blood samples: hemoglobin, 
blood urea nitrogen, creatinine, calcium, phosphorus, 
albumin, total cholesterol, triglyceride,  low-density 
Figure 1 — Flow diagram indicating patient recruitment and 
exclusion. PD = peritoneal dialysis; KT = kidney transplant; 
HD = hemodialysis; ACS = acute coronary syndrome.
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 modified clot rate assay using a Pacific Hemostasis Assay 
Set (Humlersville, nC, USA).
FLOW-MEDIATED DILATIOn (FMD)
Endothelium-dependent vasodilation was noninva-
sively assessed by determining FMD using high resolution 
ultrasonography (Logiq 7; GE Medical Systems, Milwau-
kee, WI, USA) as described previously (17). Subjects 
were informed to fast overnight, not to exercise, not to 
ingest substances that might affect FMD, such as caf-
feine, high-fat foods, or vitamin C, or use tobacco for 
at least 12 hours before the study. On the day of FMD 
measurement, blood pressure was measured three times 
with a mercury sphygmomanometer. Using ultrasonog-
raphy, baseline diameter (mean of 3 measurements) 
and peak flow velocity (mean of 2 measurements) were 
determined. Thereafter, a pressure cuff placed on the 
forearm was inflated to at least 50 mmHg above systolic 
blood pressure. After 5 minutes, the cuff was released 
to induce reactive hyperemia. After that, the maximum 
peak flow velocity was measured within 15 seconds and 
brachial artery diameter was measured between 45 and 
60 seconds. Endothelium-independent vasodilation was 
also assessed by measuring changes in brachial artery 
diameter 5 minutes after the administration of 0.4 mg 
sublingual nitroglycerine (nitroglycerine-mediated dila-
tion; nMD). This nMD test was performed 15 minutes after 
the FMD test and after obtaining a new baseline brachial 
artery diameter value. FMD and nMD were calculated as 
percentage changes in brachial artery diameter relative 
to the mean baseline diameter during reactive hyperemia 
and after administration of nitroglycerine respectively. 
All ultrasonographic measurements at each visit 
were performed by a single observer who was blinded 
to patients’ clinical information. Intraobserver within-
subjects coefficients of variation for FMD and nMD were 
8.5% ± 2.7% and 9.1% ± 1.8% respectively. All assess-
ments (i.e., residual GFR, dialysis adequacy, peritoneal 
equilibration test, and FMD) were performed simultane-
ously on the same day.
STATISTICAL AnALYSIS
Statistical analysis was performed using the statistical 
package SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). 
All data are expressed as mean ± SD or median and range 
for skewed data. The Kolmogorov–Smirnov test was used 
to analyze the normality of distribution of the measured 
parameters. Patients were divided into two groups based 
on the median value of FMD and variables were compared 
between the two groups. Results were analyzed using 
Student’s t-test and the chi-square test for normally dis-
tributed data. In addition, Pearson’s correlation analysis 
was used to elucidate the relationship between FMD and 
clinical and laboratory parameters. For skewed data, the 
Mann–Whitney U-test was used to compare variables 
between the two groups and the Spearman correlation 
coefficient was calculated to identify the relationship 
between covariates. Factors independently associated 
with FMD were determined using multivariate linear re-
gression analysis adjusted for other factors with a P value 
less than 0.10 in univariate analyses. Because skewed 
data such as residual GFR and hs-CRP violate the assump-
tion of a normal distribution, they cannot be included in 
a multiple linear regression model in an untransformed 
state. Therefore, the former was categorized into two 
groups according to the definition of anuria (i.e., residual 
GFR 1.0 mL/min/1.73 m2) (18) and the latter was log 
transformed and then entered into the final analysis. 
The level of significance was set at 0.05.
RESULTS
PATIEnT CHARACTERISTICS
The baseline characteristics of the 72 patients are 
shown in Table 1. Mean age was 48.4 ± 11.3 years, 33 pa-
tients (45.8%) were male, and mean PD duration was 
80.2 ± 50.7 months. A history of cardiovascular disease 
was noticed in only 5 patients (6.9%): 3 had coronary 
artery disease and 2 had cerebrovascular disease. Mean 
Charlson Comorbidity Index was 3.1 ± 1.3. Mean systolic 
and diastolic blood pressures were 133.3 ± 20.1 and 80.2 
± 9.7 mmHg respectively, and more than 90% of the 
subjects were taking antihypertensive medications. The 
median or mean concentrations of serum inflammatory 
markers were as follow: hs-CRP, 1.96 (0.46 – 6.86) mg/L; 
IL-6, 7.42 ± 2.87 pg/mL; and plasma fibrinogen, 486.0 ± 
88.6 mg/dL. Total and peritoneal Kt/V urea were 1.94 ± 
0.46 and 1.62 ± 0.36 respectively, and median residual 
GFR was 0.98 (0 – 9.64) mL/min/1.73 m2.
COMPARISOn OF CLInICAL AnD LABORATORY PARAMETERS 
ACCORDInG TO FMD%
Patients were divided into two groups based on the 
median value of FMD (2.41%). Compared to patients 
with FMD ≤ 2.41%, residual GFR was significantly higher 
[1.50 (0 – 9.64) vs 0.48 (0 – 3.89) mL/min/1.73 m2, P = 
0.026], whereas peritoneal Kt/V urea was significantly 
lower (1.43 ± 0.32 vs 1.82 ± 0.28, P < 0.001) in patients 
with FMD > 2.41%. However, total Kt/V urea and total 
ultrafiltration volume were not significantly different 
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between the two groups. In addition, pulse pressure 
(47.5 ± 18.9 vs 58.4 ± 17.8 mmHg, P = 0.014), serum 
hs-CRP levels [1.69 (0.46 – 5.79) vs 2.30 (0.46 – 6.86) 
mg/L, P = 0.003], and D/P Cr at 4 hours (0.68 ± 0.08 
vs 0.75 ± 0.11, P = 0.002) were significantly lower in 
patients with higher FMD%. The proportions of patients 
on renin–angiotensin system blockades or statins were 
comparable between the two groups (Table 2).
COMPARISOn OF CLInICAL AnD LABORATORY PARAMETERS 
ACCORDInG TO RESIDUAL GFR
Anuria was defined as residual GFR less than 1 mL/
min/1.73 m2 (18). Based on residual GFR value of 1 mL/
min/1.73 m2, patients were classified into lower (n = 
52) and higher RRF (n = 20) groups. As shown in Table 
3, patients with higher RRF had higher FMD% (5.03% ± 
3.99% vs 2.51% ± 1.75%, P < 0.001), shorter duration 
of PD (27.3 ± 17.3 vs 97.9 ± 45.7 months, P < 0.001), and 
lower pulse pressure (40.2 ± 15.1 vs 57.3 ± 18.4 mmHg, 
P < 0.001) than the lower RRF group. In addition, serum 
concentrations of hs-CRP [1.27 (0.46 – 2.81) vs 2.19 
(0.46 – 6.86) mg/L, P = 0.027] and plasma levels of fi-
brinogen (442.3 ± 63.5 vs 500.6 ± 91.4 mg/dL, P = 0.015) 
were significantly lower in the higher RRF group than in 
the lower RRF group (Table 3).
FACTORS ASSOCIATED WITH EnDOTHELIAL DYSFUnCTIOn
To identify factors associated with endothelial dysfunc-
tion, correlation analyses were first performed. FMD% was 
positively correlated with residual GFR and total Kt/V urea 
(γ = 0.408, P < 0.001), whereas it was inversely correlated 
with age (γ = –0.403, P < 0.001), PD duration (γ = –0.351, 
P = 0.003), pulse pressure (γ = –0.341, P = 0.003), serum 
hs-CRP levels (ρ = –0.345, P = 0.003), and D/P Cr at 4 hours 
(γ = –0.238, P = 0.044). Plasma fibrinogen levels were also 
associated with FMD% but this did not reach statistical 
significance (γ = –0.215, P = 0.069). In contrast, there 
was no significant correlation between peritoneal Kt/V 
urea and FMD% (Table 4). In a multivariate linear regres-
sion analysis adjusted for these factors, residual GFR was 
TABLE 1
Baseline Patient Characteristics
Patients (n) 72
Age 48.4±11.3 years
Gender 33 males:39 females
Body mass index 22.6±2.8 kg/m2
PD duration 80.2±50.7 months
Biocompatible PD solution 66 (91.7%)
Previous cardiovascular disease 5 (6.9%)
Charlson Comorbidity Index 3.1±1.3
Primary disease
 Chronic glomerulonephritis 35 (48.6%)
 Hypertension 19 (26.4%)
 Diabetes mellitus 12 (16.7%)
 Polycystic kidney disease 2 (2.8%)
 Others 4 (5.6%)
Systolic blood pressure 133.3±20.1 mmHg
Diastolic blood pressure 80.2±9.7 mmHg
Pulse pressure 53.1±19.0 mmHg
Medications 
 RAS blockades 51 (70.8%)
 Beta blockers 40 (55.5%)
 Calcium channel blockers 42 (58.3%)
 Statins 8 (11.1%)
 Active vitamin D 20 (27.8%)
Hemoglobin 10.7±1.7 g/dL
Calcium 8.8±0.6 mg/dL
Phosphorus 5.1±1.4 mg/dL
PTHa 237.7 (1–996.6) pg/mL
Serum albumin 3.78±0.37 g/dL
Total cholesterol 188.0±35.6 mg/dL
Triglyceride 136.7±118.1 mg/dL
HDL 53.8±15.9 mg/dL
LDL 115.7±31.8 mg/dL
Plasma fibrinogen 486.0±88.6 mg/dL
hs-CRPa 1.96 (0.46–6.86) mg/L
Interleukin-6 7.42±2.87 pg/mL
8-Isoprostanea 308.6 (50.5–1586.9) pg/mL
FMD 3.14%±2.70%
nMD 12.6%±8.0%
Residual GFRa 0.98 (0–9.64) mL/min/1.73 m2
Total Kt/V urea 1.94±0.46
Peritoneal Kt/V urea 1.62±0.36
Renal Kt/V ureaa 0.32 (0–1.66)
Total UF volume 1347.9±504.5 mL/day
Peritoneal UF volume 1053.8±577.6 mL/day
Renal UF volumea 294.2 (0–1350) mL/day
D/P Cr at 4 hours 0.71±0.10
D/D0 glucose at 4 hours 0.35±0.08
Glucose exposure 115.4±26.1 g/day
PD = peritoneal dialysis; RAS = renin–angiotensin system; PTH = parathyroid hormone; HDL = high-density lipoprotein; LDL = low-
density lipoprotein; hs-CRP = high-sensitivity C-reactive protein; FMD = flow-mediated dilation; nMD = nitroglycerine-mediated 
dilation; GFR = glomerular filtration rate; UF = ultrafiltration; D/P Cr = dialysate-to-plasma ratio of creatinine.
a Skewed data expressed as median (range).
Other data expressed as mean±SD.
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found to be an independent determinant of FMD% (β = 
0.317, P = 0.017) (Table 5).
Since there was a correlation between residual GFR 
and PD duration, two additional multivariate regression 
analyses were conducted: one excluding residual GFR 
and the other excluding PD duration in the model. The 
results of these analyses revealed that RRF remained 
as an  independent associate of FMD, whereas PD duration 
did not. In addition, we checked whether there was multi-
collinearity between residual GFR and PD duration and found 
TABLE 2
Comparison of Clinical and Laboratory Parameters According to Flow-Mediated Dilation (FMD%)
  FMD below median FMD above median
  (FMD≤2.41%) (FMD>2.41%) P Value
Patients (n) 37 35 —
Age (years) 50.6±11.8 46.0±10.3 nS
Gender (male:female) 18:19 15:20 nS
Body mass index (kg/m2) 22.9±2.3 22.4±3.2 nS
PD duration (months) 93.2±48.1 66.5±50.5 0.024
Biocompatible PD solution 34 (91.9%) 32 (91.4%) nS
Previous cardiovascular disease 3 (8.1%) 2 (5.7%) nS
Diabetes mellitus 6 (16.2%) 6 (17.1%) nS
Charlson Comorbidity Index 3.2±1.4 2.9±1.1 nS
Systolic blood pressure (mmHg) 136.3±21.3 130.1±18.6 nS
Diastolic blood pressure (mmHg) 78.0±9.2 82.6±9.8 nS
Pulse pressure (mmHg) 58.4±17.8 47.5±18.9 0.014
Medications   
 RAS blockades 27 (73.0%) 24 (68.6%) nS
 Statins 4 (10.8%) 4 (11.4%) nS
 Active vitamin D 12 (32.4%) 8 (22.9%) nS
Hemoglobin (g/dL) 10.5±1.6 11.0±1.8 nS
Calcium (mg/dL) 8.8±0.6 8.8±0.7 nS
Phosphorus (mg/dL) 5.1±1.4 5.1±1.3 nS
PTH (pg/mL)a 223.9 (1–996.0) 232.9 (6.2–711.3) nS
Serum albumin (g/dL) 3.79±0.34 3.79±0.41 nS
Total cholesterol (mg/dL) 185.0±36.9 191.1±35.2 nS
Triglyceride (mg/dL) 126.2±118.8 147.9±118.0 nS
HDL (mg/dL) 54.0±15.2 53.6±16.7 nS
LDL (mg/dL) 115.4±30.1 116.1±33.9 nS
Plasma fibrinogen (mg/dL) 499.8±90.1 471.4±85.9 nS
hs-CRP (mg/L)a 2.30 (0.46–6.86) 1.69 (0.46–5.79) 0.003
Interleukin-6 (pg/mL) 7.54±3.17 7.20±2.59 nS
8-Isoprostane (pg/mL)a 316.8 (50.5–611.9) 239.7 (55.7–1586.9) nS
Residual GFR (mL/min/1.73 m2)a 0.48 (0–3.89) 1.50 (0–9.64) 0.026
Total Kt/V urea 1.93±0.40 1.96±0.52 nS
Peritoneal Kt/V urea 1.82±0.28 1.43±0.32 <0.001
Renal Kt/V ureaa 0.10 (0–0.84) 0.30 (0–1.66) <0.001
Total UF volume (mL/day) 1350.0±545.0 1345±465.9 nS
Peritoneal UF volume (mL/day) 1150.5±571.8 951.4±574.0 nS
Renal UF volume (mL/day)a 199.5 (0–1060) 394.3 (0–1350) nS
D/P Cr at 4 hours 0.75±0.11 0.68±0.08 0.002
D/D0 glucose at 4 hours 0.33±0.08 0.38±0.07 0.004
Glucose exposure (g/day) 112.2±23.5 114.5±23.8 nS
PD = peritoneal dialysis; RAS = renin–angiotensin system; PTH = parathyroid hormone; HDL = high-density lipoprotein; LDL = 
low-density lipoprotein; hs-CRP = high-sensitivity C-reactive protein; GFR = glomerular filtration rate; UF = ultrafiltration; D/P Cr 
= dialysate-to-plasma ratio of creatinine; nS = not significant.
a Mann–Whitney U test was performed; data are expressed as median (range).
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that values of variance inflation factor for these two factors 
were 1.78 and 1.74 respectively, suggesting that there is 
little evidence of multicollinearity (data not shown).
DISCUSSION
Our results show that residual GFR is independently 
associated with endothelial function in ESRD patients 
undergoing PD, suggesting that preservation of RRF, 
even in PD patients, may be beneficial in terms of 
vascular protection.
It has been reported that endothelial dysfunction is 
significantly related to kidney function in predialysis 
patients (11,19,20) and frequently accompanies (6,7) 
chronic kidney disease (11,21), suggesting that RRF 
may contribute to vascular endothelial protection. 
However, prior to this study, it was not clear whether the 
TABLE 3
Comparison of Clinical and Laboratory Parameters According to Residual Glomerular Filtration Rate (GFR)
  Residual GFR 	 Residual GFR 
	 	 ≤1 mL/min/1.73 m2 >1 mL/min/1.73 m2 P Value
Patients (n) 52 20 —
Age (years) 49.1±11.2 46.1±11.2 nS
Gender (male:female) 25:27 8:12 nS
Body mass index (kg/m2) 22.8±2.5 22.1±3.5 nS
PD duration (months) 97.9±45.7 27.3±17.3 <0.001
Biocompatible PD solution 48 (92.3%) 18 (90%) nS
Previous cardiovascular disease 4 (7.7%) 1 (5%) nS
Diabetes mellitus 8 (15.4%) 4 (20.0%) nS
Charlson Comorbidity Index 3.1±1.4 2.8±1.0 nS
Systolic blood pressure (mmHg) 136.8±18.8 122.8±20.9 0.01
Diastolic blood pressure (mmHg) 79.4±8.2 82.6±13.3 nS
Pulse pressure (mmHg) 57.3±18.4 40.2±15.1 <0.001
Medications   
 RAS blockades 39 (75.0%) 12 (60.0%) nS
 Statins 5 (9.6%) 3 (15.0%) nS
 Active vitamin D 15 (28.8%) 5 (25.0%) nS
Hemoglobin (g/dL) 10.5±1.6 11.3±1.9 nS
Calcium (mg/dL) 8.8±0.7 8.9±0.6 nS
Phosphorus (mg/dL) 5.2±1.4 4.8±1.2 nS
PTH (pg/mL)a 217.2 (16.5–754.0) 237.7 (1–996.6) nS
Serum albumin (g/dL) 3.74±0.35 3.93±0.43 nS
Total cholesterol (mg/dL) 183.2±32.7 202.3±42.0 nS
Triglyceride (mg/dL) 121.89±100.5 181.7±154.5 nS
HDL (mg/dL) 54.8±16.2 50.9±14.9 nS
LDL (mg/dL) 112.4±29.6 125.9±36.7 nS
Plasma fibrinogen (mg/dL) 500.6±91.4 442.3±63.5 0.015
hs-CRP (mg/L)a 2.19 (0.46–6.86) 1.27 (0.46–2.81) 0.027
Interleukin-6 (pg/mL) 7.72±2.93 6.50±2.56 nS
8-Isoprostane (pg/mL)a 336.4 (122.5–1539.0) 270.3 (50.5–1586.9) nS
FMD (%) 2.51±1.75 5.03±3.99 <0.001
nMD (%) 10.08±5.40 20.2±9.85 <0.001
D/P Cr at 4 hours 0.72±0.10 0.69±0.10 nS
D/D0 glucose at 4 hours 0.35±0.08 0.36±0.08 nS
Glucose exposure (g/day) 122.5±30.2 118.0±24.4 nS
PD = peritoneal dialysis; RAS = renin–angiotensin system; PTH = parathyroid hormone; HDL = high-density lipoprotein; LDL = low-
density lipoprotein; hs-CRP = high-sensitivity C-reactive protein; FMD = flow-mediated dilation; nMD = nitroglycerine-mediated 
dilation; D/P Cr = dialysate-to-plasma ratio of creatinine; nS = not significant.
a Mann–Whitney U test was performed; data are expressed as median (range).
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 maintenance of endothelial integrity in ESRD patients is 
still affected by RRF. Wang et al. (22) attempted to clarify 
this issue by measuring serum levels of soluble vascular 
cell adhesion molecule-1, a marker of endothelial dys-
function, and found that there was a significant inverse 
correlation between levels of this marker and RRF in 
long-term PD patients; however, no functional imaging 
was performed in that study. In addition, arterial stiff-
ness measured by brachial–ankle pulse wave velocity was 
inversely correlated with RRF in a retrospective study 
of 146 PD patients (23). In line with these findings, we 
evaluated endothelial function using FMD in the present 
study and, based on our findings, suggest that endothe-
lial function is significantly affected by RRF, even in ESRD 
patients with low RRF and considerable PD duration. In 
contrast, Cheng et al. found that endothelial dysfunction 
was closely associated with volume overhydration but 
not with RRF in PD patients (24). This discrepancy may 
partly be due to some differences in the demographic 
characteristics of patients: patients were younger and 
less obese in our study. In addition, differences in the 
volume status of the patients may also contribute to 
these divergent results. In the present study, we ex-
cluded from the analysis patients with any clinical signs 
of volume overload. nevertheless, since assessment of 
volume status based on clinical parameters may not be 
accurate, a more reliable method would be helpful to 
evaluate volume status in these patients.
Preservation of RRF is of paramount importance in 
patients with ESRD (9,10). It is widely acknowledged 
that fluid overload, anemia, and malnutrition are less 
common in patients with higher RRF compared to those 
with lower RRF (9). In addition, blood pressure is better 
controlled (25,26) and serum concentrations of inflam-
matory markers are lower in patients with preserved 
RRF (27,28). Based on the fact that hypertension and 
inflammation are key contributors to the development 
of atherosclerosis (29,30), it can be presumed that en-
dothelial dysfunction may be more evident in patients 
with lower RRF due to higher blood pressure and inflam-
mation. In fact, in the present study, blood pressure and 
concentrations of serum hs-CRP and plasma fibrinogen 
were significantly higher in patients with residual GFR ≤ 
1 mL/min/1.73 m2 compared to those with residual GFR 
> 1 mL/min/1.73 m2, which might contribute to worse 
endothelial function in the former group.
Interestingly, Pearson’s correlation analysis revealed 
that there was a significant correlation between FMD% 
and total Kt/V urea (the sum of peritoneal and renal Kt/V 
urea), suggesting a possible effect of dialysis adequacy 
on endothelial dysfunction. When each component of 
Kt/V urea was analyzed individually, however, FMD% 
was significantly associated with renal Kt/V but not with 
peritoneal Kt/V. In addition, renal Kt/V urea and RRF were 
significantly higher in patients with higher FMD% relative 
to those with lower FMD%. Moreover, RRF was found to be 
an independent predictor of FMD% in multivariate linear 
TABLE 5
Multivariate Linear Regression for Flow-
Mediated Dilation (FMD)a
 β P Value
Residual GFRb >1 mL/min/1.73 m2 0.317 0.017
Age –0.357 0.002
Peritoneal Kt/V urea –0.103 0.333
PD duration 0.001 0.993
Log hs-CRP –0.397 0.004
Fibrinogen 0.158 0.300
Pulse pressure –0.032 0.785
D/P Cr at 4 hours –0.060 0.579
GFR = glomerular filtration rate; PD = peritoneal dialysis; 
hs-CRP = high-sensitivity C-reactive protein; D/P Cr = dialysate-
to-plasma ratio of creatinine.
a Adjusted for residual GFR, peritoneal Kt/V urea, PD duration, 
pulse pressure, age, log hs-CRP, fibrinogen, and D/P Cr at 
4 hours.
b Compared to patients with residual GFR ≤ 1 mL/min/1.73 m2.
TABLE 4
Factors Associated with Flow-Mediated Dilation (FMD)
 Correlation coefficient P Value
Residual GFRa 0.381 0.001
PD duration –0.351 0.003
Total Kt/V urea 0.408 <0.001
Peritoneal Kt/V urea –0.160 0.178
Renal Kt/V ureaa 0.584 <0.001
Age –0.403 <0.001
Pulse pressure –0.341 0.003
Hemoglobin 0.008 0.946
Calcium × phosphorus –0.028 0.815
Total cholesterol 0.080 0.504
LDL cholesterol 0.180 0.367
hs-CRPa –0.345 0.003
Fibrinogen –0.215 0.069
Interleukin-6 –0.167 0.168
8-Isoprostanea –0.155 0.234
D/P Cr at 4 hours –0.238 0.044
GFR = glomerular filtration rate; PD = peritoneal dialysis; LDL = 
low-density lipoprotein; hs-CRP = high-sensitivity C-reactive 
protein; D/P Cr = dialysate-to-plasma ratio of creatinine.
a Spearman correlation analysis was conducted for the skewed 
data.
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regression analysis. In contrast, such associations were 
not observed between peritoneal Kt/V urea and FMD%. 
The results of the present study suggest that RRF rather 
than peritoneal clearance per se may better contribute 
to preservation of vascular endothelial function.
The aging process accelerates atherosclerosis in 
general (31) and numerous studies have demonstrated 
that age is significantly correlated with endothelial 
dysfunction (30,32). In agreement with those studies, 
old age was revealed as a strong determinant of en-
dothelial dysfunction in this study. In addition, serum 
inflammatory markers such as hs-CRP, which is one of 
the key players in atherosclerosis, were independently 
associated with endothelial dysfunction. In contrast, 
even though pulse pressure was inversely correlated 
with FMD% in the Pearson’s correlation analysis, mul-
tivariate regression analysis disclosed that it was not 
independently associated with endothelial dysfunction. 
This may be partly explained by the confounding ef-
fect of RRF. A loss of RRF was reported to be associated 
with higher arterial pulse pressure (33). Our study also 
showed that pulse pressure was significantly higher 
in patients with lower residual GFR. Interestingly, when 
RRF was not entered into the multivariate analysis, 
pulse pressure became modestly associated with FMD% 
(β = –0.193, P = 0.081; data not shown). Moreover, 
pulse pressure showed a significant inverse correla-
tion with residual GFR (ρ = –0.446, P < 0.01; data 
not shown). Based on these findings, pulse pressure 
appears to be related to RRF, resulting in lack of an 
independent association between this parameter and 
endothelial dysfunction.
Several recent studies have suggested that perito-
neal solute transport may also affect vascular function 
in PD patients. Zhe et al. (34) found that D/P Cr at 
4 hours was a significant predictor of arterial stiffness, 
while such an association was not observed in two 
other studies (23,35). In the present study, D/P Cr at 
4 hours was associated with FMD% only in the Pearson’s 
correlation analysis, not in the multivariate analysis. 
Even though Zhe et al. (34) suggested that high peri-
toneal transport might be simply attributable to the 
generalized vascular disorder related to accelerated 
atherosclerosis, the association between peritoneal 
transport and endothelial dysfunction remains to be 
further investigated.
Several shortcomings of this study should be dis-
cussed. First, this was a cross-sectional study with a 
relatively small sample size. A cross-sectional design does 
not allow cause-and-effect relationships to be drawn 
between RRF and endothelial dysfunction. It is possible 
that RRF contributes to better endothelial function, 
directly or indirectly. Alternatively, better endothelial 
function might contribute to greater preservation of 
RRF. Hence, the causality of our findings should not 
be over interpreted and requires further confirmation. 
All data were collected at a single time; therefore, they 
do not represent the precise and usual status of the 
patients. Particularly, the measurement accuracy of 
RRF with 24-hour urine collections can be variable. In 
addition, there is a possibility that selection bias due 
to a relatively small sample size might have distorted 
our data. The study subjects were also relatively young 
and had a low prevalence of cardiovascular diseases and 
diabetes. Therefore, it is possible that the proportion of 
patients with severe endothelial dysfunction included 
in the present study was low. Moreover, the duration 
of PD in our subjects was long, with low RRF, and thus 
our patient group may not be a representative cohort of 
dialysis patients in Korea. 
Second, in this study, we excluded patients with 
volume overload based on clinical findings only, which 
may not be accurate in assessing volume status. Fur-
thermore, because volume status is largely dependent 
on RRF in ESRD patients, and fluid overload per se can 
induce hypertension, a key factor that leads to vascular 
dysfunction, more accurate assessment using bioimped-
ance or measurement of inferior vena cava diameter 
would be informative and might allow detection of subtle 
differences in the fluid status of patients. Consider-
ing these facts, we surmise that the impact of volume 
status on the results of the present study cannot be 
completely disregarded. 
Third, other measures, such as pulse wave velocity 
and carotid intima medial thickness, that would comple-
ment this study were not performed. In fact, FMD is a 
surrogate marker of vascular health and may not be a 
good measure of vascular function. nevertheless, FMD 
is well known as a noninvasive and reproducible tool 
and is the most commonly used assessment tool of en-
dothelial function (36) with prognostic significance in 
ESRD patients (8). 
Finally, patients undergoing hemodialysis were not 
included in the present study. Considering the results 
of recent studies indicating the important contribution 
of RRF to overall survival in hemodialysis patients (37), 
we expect to see a similar effect of RRF on endothelial 
dysfunction in patients on hemodialysis as well.
In conclusion, our results suggest that higher RRF is 
associated with better endothelial function in patients 
with ESRD, even in patients with low RRF and considerable 
PD duration. Further studies in a larger, less selective 
population of incident PD patients with earlier stages of 
PD and higher RRF are needed to confirm our findings.
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